

SOHO ASIA 2026

January 23(Fri) - 25(Sun) Taipei, Taiwan

Evergreen International Convention Center 10F/11F

Friday, January 23, 2026 DAY-1

Satellite Symposium - Astellas - Room1101

13:10~13:50

13:10~13:50	Optimizing Post-HSCT Maintenance Strategies for R/R FLT3m+ AML Management	Moderator : Speaker : SINGH Gill Harinder Harry (University of Hong Kong)

Room 1101
Chronic Lymphocytic Leukemia (CLL)

14:00~15:15

Moderator : William G. Wierda (MDACC)
Gin Gin Gan (Universiti Malaya)

Time	Topic	Speaker
14:00~14:25	BTKIs + BCL2 Inhibitors in CLL Frontline Therapy (Online)	Philip Thompson (Peter MacCallum Cancer Centre, Australia)
14:25~14:50	Sequencing Treatment for Relapsed/Refractory CLL (Online)	Adam Kittai (Mount Sinai School of Medicine,USA)
14:50~15:15	Non-Covalent BTKi	William G. Wierda (MDACC)
15:15~15:35	BREAK	

Room 1101
Classical Hematology-1

15:35~16:50

Moderator : Jong Wook Lee (Hanyang University Seoul Hospital, Korea)
Raymond Siu Ming Wong (Chinese University of Hong Kong)

Time	Topic	Speaker
15:35~16:00	Optimizing Complement Inhibitor Strategies in Paroxysmal Nocturnal Hemoglobinuria Care	Danny Hsu (Liverpool Hospital, Australia)
16:00~16:25	Practical Implementation and Unmet Needs in Asia-Pacific (Online)	Bing Han (Peking Union Medical College Hospital)
16:25~16:50	The Evolving Landscape of ITP: From First-Line to Precision Targeting in Refractory Disease	Jun Ho Jang (Samsung Medical Center, Korea)

Saturday, January 24, 2026 DAY-2

BREAKFAST symposium (1) - TTY - Room 1101 08:00~08:40

Chemo-Free Care Pathway for R/R DLBCL

Moderator :

Speaker : Hung Chang
(Chang Gung Memorial Hospital)

BREAKFAST symposium (2) - Roche - Room 1001 (10F) 08:00~08:40

How to Optimize Treatement Options for Frontline DLBCL Patients?

Moderator :

Speaker : Tran-Der Tan
(Koo Foundation Cancer Center)

08:40~08:50 BREAK

Opening Remarks - HST chairman 08:50~09:00

Opening Remarks - SOHO chairman 09:00~09:10

Room 1101
Acute Myeloid Leukemia (AML) 09:10~10:50

Moderator : Naval Daver (MDACC)
Andrew Wei (Peter MacCallum Cancer Centre, Melbourne)
LEUNG Yu Hung, Anskar (University of Hong Kong)

Time	Topic	Speaker
09:10~09:35	Optimizing Treatment Strategies for Younger and Fit Patients with AML	Andrew Wei (Peter MacCallum Cancer Centre, Australia)
09:35~10:00	The MD Anderson Approach with Triplet Regimens in AML	Naval Daver (MDACC)
10:00~10:25	Optimizing Treatment Strategies for Unfit Patients with AML	Hee Je Kim (The Catholic University of Korea, Korea)
10:25~10:50	The Evolving Role and Future Perspectives of MRD in AML	Richard Dillon (King's College London, UK)

10:50~11:00 BREAK

Room 1101
Myelodysplastic Neoplasm (MDS) 11:00~12:15

Moderator : Seishi Ogawa (Kyoto University, Japan)

Time	Topic	Speaker
11:00~11:25	Classification and risk stratification of MDS	Hsin-An Hou (NTUH)
11:25~11:50	Risk Stratification and Treatment for CMMoL	Ayalew Tefferi (Mayo Clinic)
11:50~12:15	Novel Treatment for MDS (Online)	Guillermo Garcia-Manero (MSACC)

12:15~12:25 BREAK

LUNCH symposium (1) - Novartis - Room 1101 12:25~13:05

A New Era in CML Treatment: Evolving Algorithms Driven by New Drug Approvals (Online)

Moderator :

Speaker : Dennis Kim
(Princess Margaret Cancer Center, Canada)

LUNCH symposium (2) - AZ - Room 1001 (10F) 12:25~13:05

Reshaping the Treatment Outcome for CLL Patients

Moderator :

Speaker :

13:05~13:15 BREAK

Saturday, January 24, 2026 DAY-2

Room 1101
Chronic Myeloid Leukemia (CML)

13:15~14:30

Moderator :

Time	Topic	Speaker
13:15~13:40	Evolving landscape of Frontline CML Therapy in 2026 (Online)	Hagop Kantarjian (MDACC)
13:40~14:05	Overcoming TKI Resistance in CML: Strategies for Salvage Therapy and Novel Agents (Online)	Elias Jabbour (MDACC)
14:05~14:30	When, Who and How to Perform TFR	
14:30~15:10	*POSTER SESSION*	

Room 1101
Lymphoma-1

15:10~16:25

Moderator : Jason Westin (MDACC)
TSE Wai Choi, Eric (University of Hong Kong)

Time	Topic	Speaker
15:10~15:35	Can we get rid of chemotherapy for DLBCL?	Jason Westin (MDACC)
15:35~16:00	Recent Progress in Follicular Lymphoma and Marginal Zone Lymphoma (Online)	John Leonard (Weill Cornell Medicine, USA)
16:00~16:25	Recent Progress in Mantle Cell lymphoma - Small molecules, Biologics, and Cell Therapy (Online)	Michael (Luhua) Wang (MDACC)
16:25~16:35	BREAK	

Room 1101
Classical Hematology – 2

16:35~17:50

Moderator : Alok Srivastava (Christian Medical College, India)

Time	Topic	Speaker
16:35~17:00	Recent Advancements and Emerging Therapies in the Management of Severe Aplastic Anemia (SAA) (Online)	Kohei Hosokawa (Kanazawa University Hospital, Japan)
17:00~17:25	Diagnostic Approach and Therapeutic Strategies in Cold Agglutinin Disease (Online)	Yasutaka Ueda (Osaka University, Japan)
17:25~17:50	Optimizing Conditioning for HSC Based Gene Therapy	Alok Srivastava (Christian Medical College, India)

Sunday, January 25, 2026 DAY-3

BREAKFAST symposium (3) - Otsuka - Room 1101 08:00~08:40

Shaping Frontline Treatment in Ph+ ALL:
Real-World Experience with Next-Generation TKI

Moderator :
Speaker : Jae Ho Yoon
(Seoul St. Mary's Hospital, Korea)

BREAKFAST symposium (4) - J&J - Room 1001 (10F) 08:00~08:40

New Era of NDMM Treatment

Moderator :
Speaker : Robert Z. Orlowski
(MDACC)

08:40~08:50 BREAK

Room 1101
Multiple Myeloma 08:50~10:30

Moderator : Robert Z. Orlowski (MDACC)
Ja Min Byun (Seoul National University College of Medicine, Korea)

Time	Topic	Speaker
08:50~09:15	First-Line Treatment of Multiple Myeloma	Jeffrey Huang (NTUH, Taiwan)
09:15~09:40	RR Treatment	Robert Z. Orlowski (MDACC)
09:40~10:05	Bispecific T-Cell Engager & CAR-T Therapy for Multiple Myeloma (Online)	Omar Nadeem (Dana Farber Cancer Institute, USA)
10:05~10:30	MRD-Guided Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma (Online)	Oren Pasvolsky (MDACC)

Oral presentation – 1 10:30~10:40

Oral presentation – 2 10:40~10:50

10:50~11:00 BREAK

Room 1101
Cell Therapy 11:00~12:15

Moderator : John Dipersio (Washington at St. Louis, USA)
Junichiro Yuda (National Cancer Center Hospital East, Japan)

Time	Topic	Speaker
11:00~11:25	Off-the-Shelf Allogeneic CAR-T for the Treatment of T Cell Malignancies	John Dipersio (Washington at St. Louis, USA)
11:25~11:50	Toxicity Management for CAR-T	Allen Yeoh (National University Hospital, Singapore)
11:50~12:15	Strategies on Integrating Next-Generation CAR-T Therapy and Transplantation	

12:15~12:25 BREAK

LUNCH symposium (3) - Pfizer - Room 1101 12:25~13:05

Optimizing treatment strategies with BCMA BsAbs for RRMM (Online)

Moderator :
Speaker :Alexander M. Lesokhin
(Memorial Sloan Kettering cancer center)

LUNCH symposium (4) - GSK - Room 1001 (10F) 12:25~13:05

Comprehensive Control for Patients with Anemic Myelofibrosis

Moderator :
Speaker : Gabriela Hobbs
(Mass General Research Institute, USA)

13:05~13:15 BREAK

Sunday, January 25, 2026 DAY-3

13:15~13:55 *POSTER SESSION*

Room 1101
Myeloproliferative Neoplasm (MPN)

13:55~15:10

Moderator : Keita Kirito (University of Yamanashi, Japan)

Time	Topic	Speaker
13:55~14:20	Diagnosis and Treatment for Polycythemia Vera and Essential Thrombocythemia	Sung-Eun Lee (Seoul St. Mary's Hospital, Korea)
14:20~14:45	A Recent Progress of PV and ET with Ropeg Interferon	Keita Kirito (University of Yamanashi, Japan)
14:45~15:10	Diagnosis and Treatment for MF (Online)	Prithviraj Bose (MDACC)
15:10~15:20	BREAK	

Room 1101
Acute Lymphoblastic Leukemia (ALL)

15:20~16:35

Moderator : Dr. (Brig.) Tathagata Chatterjee (Indian Society of Hematology)

Time	Topic	Speaker
15:20~15:45	Research and Therapy of Frontline Ph-Positive and B-Cell ALL at MD Anderson in 2026 (Online)	Hagop Kantarjian (MDACC)
15:45~16:10	Building a Better Cure: Evolving TPOG Strategies for Childhood ALL in Taiwan	Hsi-Che Liu (MacKay Memorial Hospital)
16:10~16:35	Optimizing Outcomes in R/R ALL: How to Sequence Immunotherapy Options (Online)	Elias Jabbour (MDACC)
16:35~16:45	BREAK	

Room 1101
Lymphoma – 2

16:45~18:00

Moderator : Lawrence Ng Cheng Kiat (Singapore General Hospital, Singapore)

Time	Topic	Speaker
16:45~17:10	Sequencing CAR-T and Bispecific T-Cell Engager for Large B-Cell Lymphoma	Caron A. Jacobson (Dana Farber, USA)
17:10~17:35	Progress and Strategy on Treating Primary Central Nervous System Lymphoma (Online)	Kate Cwynarski (Washington University, London, UK)
17:35~18:00	Progress and Strategy on Treating Peripheral T-Cell Lymphoma	Kerry J. Savage (Vancouver, Canada)

Closing Remarks – HST chairman 18:00~18:05

Closing Remarks – SOHO chairman 18:05~18:15

ADAM KITTAI, MD, MBA

APPOINTMENTS/EMPLOYMENT

07/2019-04/2024	Assistant Professor – Clinical, Division of Hematology Department of Internal Medicine The Ohio State University, Columbus, OH
05/2024-Present	Associate Professor – Hematology and Medical Oncology Assistant Director of Lymphoma Clinical Research CLL Clinical Research Leader Department of Medicine Icahn School of Medicine at Mount Sinai Hospital, New York, NY

EDUCATION

Degrees:

08/2008-05/2012	M.D. Granted in 05/2012 New York State/American Program Tel Aviv University, Sackler School of Medicine
07/2015-07/2016	Chief Resident – Department of Internal Medicine George Washington University Medical Center Veterans Affairs Medical Center Chief Resident Washington, DC
07/2018-06/2019	Chief Fellow – Division of Hematology/Oncology Oregon Health & Science University Hematology/Oncology Fellowship Program Portland, Oregon, OR
09/2022-08/2025	M.B.A Granted in 08/2025 Fisher College of Business: The Ohio State University Columbus, OH

Fellowships, Internships, Residency:

07/2012-06/2013 Intern in Internal Medicine
George Washington University Medical Center
07/2013-06/2015 Resident in Internal Medicine
George Washington University Medical Center
07/2016-06/2019 Fellow in Hematology/Oncology
Oregon Health & Science University

CERTIFICATION

10/08/2015	American Board of Internal Medicine, Internal Medicine
11/26/2019	American Board of Internal Medicine, Oncology
11/17/2020	American Board of Internal Medicine, Hematology

HONORS/AWARDS

07/2017	National – ASCO/AACR Workshop on Methods in Clinical Research
05/2018	Health System – Oregon Health & Science University Tartar Trust Recipient
07/2018	International – ASH Research Training Award for Fellows
01/2019	National – NIH LRP Awardee
07/2019	National – NIH DCTD LOI Writing Workshop
05/2020	Health System – OSU Internal Medicine Inpatient Attending Teaching Award
07/2020	National – ASH Clinical Research Training Institute
05/2021	Health System – OSU Excellence in Teaching Award
12/2022	International – ASCO Conquer Cancer Career Development Award

PUBLICATIONS

H Index – 20 – 11/24/2025

- Peer Reviewed Original Contributions
- 60 Peer reviewed Scientific Research Articles

CURRICULUM VITAE

Jun Ho Jang

Address: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Date and Place of Birth: Octover 19, 1967, Seoul, Korea

Sex: Male

Present Position: Professor,
Division of Hematology- Oncology
School of Medicine, Samsung Medical Center,
SungKyunKwan University, Seoul, Korea

Membership of academic societies: The Korean Society of Hematology
The Korean Society of Hematopoietic Stem Cell Transplantation
The American Society of Hematology
The European Hematology Association

EDUCATION:

1986- 1992	Yonsei University College of Medicine, Seoul, Korea
1992	M.D. No.46514, Korea
1998- 2000	Master Degree, Graduate School, Yonsei University, Seoul, Korea
2000	Korean Board of Internal Medicine No.6448
2000- 2002	Ph.D Degree, Graduate School, Yonsei University, Seoul, Korea
2002- 2004	Post- Doctoral fellowship, University of Michigan, Ann Arbor, USA

Andrew Wei

Professor Andrew Wei (MBBS, PhD, FAHMS) is a clinical haematologist and co-stream lead for acute leukaemia and myelodysplastic syndromes at the Peter MacCallum Centre and the Royal Melbourne Hospital in Melbourne, Australia. Dr Wei is jointly appointed as a laboratory head in the Division of Blood Cells and Blood Cancers at the Walter and Eliza Hall Institute of Medical Research (WEHI), where his laboratory conducts translational research into acute myeloid leukaemia. He has chaired the Acute Leukemia Working party for the Australasian Leukaemia and Lymphoma Group from 2009-2025 and is an international expert in AML, leading clinical trial programs that have contributed to regulatory approvals and changes in clinical practice. His areas of expertise are acute myeloid leukemia, new therapeutic targets and development of clinical trials focussed on targeting measurable residual disease and *TP53* mutation.

Prof. Hee-Je Kim, M.D., Ph.D.
Division of Hematology, Department of Internal Medicine, Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 06591

SIGNATURE

2025-Now: Executive Board member of APBMT
2023-Now: Auditor of Korean Marrow Donor Program (KMDP);
2023-Now: Executive Board member of Asia Pacific Leukemia Consortium (APLC);
2021-Now: Vice President of Asian Cellular Therapy Organization (ACTO);
2017-Now: Associate Editors of Blood Cell Therapy (APBMT) & Mediterranean Journal of Hematology and Infectious Diseases & Biomedicines
2015-Now: Board member of Korean Blood Diseases & Cancer Association (KBDCA);
2023-2025: Auditor General, KSBMT (Old)
2021-2025: Director of Catholic Hematology Hospital (Old), Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea;
2021-2023: Chairman of KSBMT (Old)

RESEARCH & AWARDS

Korea Health 21' and the National Cancer Control R&D Program, and the National Research Foundation of Korea 25'
Awards, Outstanding Researcher and Lifetime Achievement Awards from Korean Society of Hematology & Korean Society of Blood and Marrow Transplantation
Associate Editor for *Blood Cell Therapy* (APBMT), *Biomedicines*, and the *Mediterranean Journal of Hematology and Infectious Diseases*

BIBLIOGRAPHY

1. Objectively measured physical function predicts mortality in older adults with acute myeloid leukemia by lower-intensity therapy: a prospective cohort study. **J Geriatr Oncol** 2025 Nov; 16(8):102335.
2. Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia. **Haematologica** 2024 Apr; 109(4):1095-1106.
3. Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML. **Front Oncol** 2023 Nov;13:1281782. eCollection 2023.
4. A successful bridge therapy combining hypomethylating agents with venetoclax for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia. **Cancers** 2023 Mar 8;15(6):1666.
5. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: A propensity score-matched analysis. **Blood Cancer J** 2022 Dec;12(12):169.
6. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. **Blood** 2022 Mar; 139(11):1646-1658.
7. A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML). **Ther Adv Hematol** 2022 Mar 23; 13:20406207221081637.
8. Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis. **Cancers** (Basel) 2021 Dec 14;13(24):6285.

Curriculum Vitae: Dr. Richard James Dillon

General Medical Council registration number: 6103271 (licensed, practicing physician)

Current Positions:

Group Leader and Clinical Senior Lecturer, Molecular Haematology Group.
Department of Medical and Molecular Genetics, King's College, London (appointed November 2016)

Consultant Haematologist and Clinical Service Lead for Acute Leukaemia and Molecular Diagnostics
Guy's and St Thomas' NHS Foundation Trust, London (appointed May 2016)

Qualifications

2016	PhD	"The Biology of Acute Promyelocytic Leukaemia and Therapy-Related Myeloid Leukaemias"
2011	FRCPath	Fellow of the Royal College of Pathologists of London
2008	MRCP (UK)	Member of the Royal College of Physicians of London
2004	MBBS	University of London (University College and Royal Free Medical School)
2001	BA	Physiological Science, University of Oxford, 1st Class Honours

Professional commitments

VICTOR (phase 2 randomised trial)	Chief Investigator
OPTIMISE-FLT3 (phase 3 randomised trial)	Co-chief Investigator, molecular lead
OVATION (phase 3 randomised trial)	Co-chief Investigator, molecular lead
NCRI AML19 (phase 3 randomised trial)	Lead for molecular diagnostics, MRD monitoring and APL.
MyeChild01 (phase 3 randomised trial)	Lead for molecular diagnostics and MRD monitoring
Abbvie VIALE-M (phase 3 randomised trial)	UK Chief Investigator
UK AML research consortium	Member, molecular MRD and APL lead.
ASH international consortium on AML	Member, co-chair of laboratory committee
European Leukaemia Net	ELN-DAVID Board member and UK representative
Blood Cancer UK	Clinical Advisory Panel Member
KCL Cancer Genetics BSc programme	Module organiser

Doctoral Students

William Villiers (graduated)	Supervisor
Leena Halim (graduated)	Supervisor
Jad Othman (year 3)	Co-supervisor with Prof. Harry Iland
Phoebe Aucken (year 1)	Co-supervisor with Dr. Lynn Quek
Aditya Tedjaseputra (year 1)	Co-supervisor with Prof. Andrew Wei

Publications

Please see Google Scholar (https://scholar.google.com/citations?hl=en&user=aHP6HRcAAAAJ)

Metrics (September 2025)
Total publications = 206
Total citations = 4024
H-index = 31

BIO

Dr. Elias Jabbour serves as **Professor of Medicine** and **Chief of the Acute Lymphoblastic Leukemia (ALL) Section** within the Department of Leukemia at **The University of Texas MD Anderson Cancer Center** in Houston, Texas. His research is centered on **translational and clinical developmental therapeutics** in leukemia, with a particular emphasis on advancing novel treatment paradigms across disease subtypes.

Over the past two decades, Dr. Jabbour has made seminal contributions that have significantly enhanced **prognosis, survival outcomes, and therapeutic strategies** for patients with various forms of leukemia. His work is reflected in an extensive body of scholarship, with more than **1,000 peer-reviewed publications**, underscoring his leadership and impact in the field of hematologic malignancies.

Jason R. Westin, MD, MS

Professor, Department of Lymphoma & Myeloma
Director, Lymphoma Clinical Research Program
Section Chief, Aggressive & Indolent Lymphomas
The University of Texas MD Anderson Cancer Center — Houston, Texas

Professional Summary
Internationally recognized lymphoma oncologist and clinical trialist leading innovative, response-adapted and cellular-therapy-based approaches for diffuse large B-cell lymphoma (DLBCL). Principal investigator of multiple pivotal phase II/III trials including CAR-T, bispecific antibodies, and ctDNA-guided therapy. National advocate for oncology policy and drug-shortage solutions; elected to the ASCO Board of Directors (2025–2029).
Leadership & Academic Roles

Member, ASCO Board of Directors (2025–2029)
Executive Leadership, Lymphoma-Myeloma Service Line, MD Anderson (2024–Present)
Section Chief, Indolent Lymphoma (2024–Present)
Director, Lymphoma Clinical Research Program (2019–Present)
Section Chief, Aggressive Lymphoma (2019–Present)
Past Chair, ASCO Government Relations Committee & Finance Committee
ASH Clinical Research Training Institute Mentor (2024–Present)

Clinical & Research Focus
Diffuse large B-cell lymphoma and high-risk lymphoma therapeutics
CAR-T cell therapy, bispecific antibodies, targeted combinations
Minimal residual disease / ctDNA integration
Drug shortage policy and health-care advocacy

Selected Research Leadership
Steering Committee Chair, SUNMO (mosunetuzumab + polatuzumab) Phase III
Steering Committee Chair, LOTIS-9 (loncastuximab + rituximab) Phase III
Steering Committee, ZUMA-23 (axi-cel frontline high-risk LBCL) Phase III
Principal Investigator, multiple national and global early- and late-phase studies
Developer & PI, Smart Start and Smart Stop trials

Over 250 peer-reviewed publications, hundreds of invited lectures nationally & internationally

Education & Training
MD, University of Florida (AOA)
MS, Clinical & Translational Science, UTHealth Houston
Fellowship, Hematology/Oncology, MD Anderson Cancer Center
Residency, University of North Carolina

Curriculum Vitae

IDENTICAL INFORMATION

Name : Keita Kirito
Business Address : Department of Hematology/Oncology , University of Yamanashi,

EDUCATIONAL HISTORY

1982	Graduated from Kofu-nishi High School (Kofu)
1988	M.D. Jichi Medical School
1998	Ph.D. (Dr.of Medical Science) Jichi Medical School

PROFESSIONAL BACKGROUND (EMPLOYMENT HISTORY)

May/1988	passed the Examination of National Board
May/1988-May/1990	Resident in Yamanashi Central Hospital
June/1990-March/1994	Medical Staff, Department of internal Medicine, Yamanashi Red Cross Hospital
April/1998-	Assistant professor, Department of Hematology, Jichi Medical School
December/2001-June/2002	Visiting Assistant professor, Department of Hematology, University of Washington
July/2002-June/2004	Assistant Research Scientist, Department of Hematology, University of California, San Diego
July/2004-December/2004	Assistant professor, Department of Hematology, Jichi Medical School
January/2005-December/2009	Associate professor, Department of Hematology/Oncology, University of Yamanashi
January/2010-present	Professor , Department of Hematology/Oncology, University of Yamanashi

LICENSE AND CERTIFICATION

1988	Japanese Medical License Registration

MEMBERSHIPS

Japanese Society of Hematology
Japanese Society of Internal Medicine
The Japanese Biochemical Society
The Japanese Cancer Association
American Society of Hematology

Name	Sung-Eun Lee
Current Position & Place of Work	Professor/ Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Country	Republic of Korea
Major Field	Hematology (Myeloproliferative neoplasms, CML, Stem cell transplantation)

Educational Background

March 1997 – February 2003	Bachelor's degree The Hanyang Univ. of Korea, Seoul, Korea
March 2009 – February 2013	Ph.D. degree The Catholic Univ. of Korea, Seoul, Korea

Professional Experience

March 2003 – February 2009	Internship & Residency The Hanyang Univ. of Korea, Seoul, Korea Department of Internal Medicine, The Catholic University of Korea
March 2009 – February 2013	Clinical Fellow, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea
March 2013 – February 2016	Clinical assistant professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea
March 2016 – March 2018	Assistant professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea
March 2018 – November 2019	Postdoctoral Fellow, MD Anderson cancer center
April 2018 – February 2023	Associate professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea
March 2023 –	Professor, Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea

Other Experience and Professional Memberships

1. Korean Society of Hematology
2. Korean Society of Hematopoietic Stem Cell Transplantation
3. Korean Society of Internal Medicine
4. Korean Medical Association
5. Korean Society of Experimental Hematology
6. Working group on cardio-oncology
7. CML Working Party, Korean Society of Hematology
8. MPN Working Party, Korean Society of Hematology

CURRICULUM VITAE

Name Hsi-Che Liu

Current Position
- Professor, School of Medicine, MacKay Medical University
- Director, Division of General Pediatrics, MacKay Children's Hospital
- Senior Attending Physician, Division of Pediatric Hematology/Oncology, MacKay Children's Hospital

Education
1991 M.D. Department of Medicine, Chung Shan Medical University

Professional Experience
- 2002-2003 Postdoctoral research, Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, US
- 2007-2017 Director, Division of Pediatric Hematology/Oncology, MacKay Children's Hospital
- 2017-Present Principal Investigator, Taiwan Pediatric Oncology Group (TPOG) Acute Lymphoblastic Leukemia Study
- 2017-Present Member, Ponte di legno Meeting

Field of Research
Childhood leukemia, molecular biology and therapy

Major Publications

1. Yeh T-C, Liu H-C, Hou J-Y, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. *Cancer.* 2014; 120(8), 1255.
2. Liu H-C, Yeh T-C, Hou J-Y, et al. Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. *J Clin Oncol*. 2014; 32: 1825.
3. Yen H-J, Chang W-H, Liu H-C, et al. Outcomes following discontinuation of E. coli L-asparaginase upon severe allergic reactions in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2016 Apr; 63(4):665.
4. Li M-J, Liu H-C, Yen H-J, et al. Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and CNS preventive therapy without cranial radiation. *Pediatr Blood Cancer.* 2017 Feb; 64: 234.
5. Yeh T-C, Liang D-C, Hou J-Y, et al. Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal treatment and omission of prophylactic cranial irradiation: results of the Taiwan Pediatric Oncology Group (TPOG)-ALL-2002 Study. *Cancer*. 2018 Dec 1;124(23): 4538.
6. Yeh T-C, Liang D-C, Liu H-C, et al. Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan. *Pediatr Blood Cancer.* 2019 Jan;66(1): e27496.
7. Yeh T-C, Hou J-Y, Huang T-H, Lu C-H, Sun F-J, Huang, Liu H-C. Effectiveness and antimicrobial susceptibility profiles during primary antimicrobial prophylaxis for pediatric acute myeloid leukemia. *Sci Rep.* 2021 Oct 27;11(1):21142.
8. Liu H-C, Huang Y-J, Jaing T-H, et al. Refining risk stratification in pediatric B-acute lymphoblastic leukemia: combining IKZF1 plus and Day 15 MRD positivity. Br J Haematol. 2024 Apr;204(4):1344.
9. Huang Y-J, Liu H-C, Kuo M-C, et al. Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan. Br J Haematol. 2025 Jun;206(6):1699.

Dr. Kerry Savage is a Medical Oncologist at BC Cancer and a Professor of Medicine (tenure track) at the University of British Columbia (UBC). She received a BSc (Biology (Genetics) and a M.D. from UBC. She completed a post-doctoral research fellowship in lymphoma at the Dana-Farber Cancer Institute in Boston, MA, and earned a MSc in Epidemiology from the Harvard School of Public Health. She is the Business Unit Leader for the lymphoma/myeloma and melanoma BC Cancer Vancouver clinical trial group. She is on the Scientific Advisory Board for the Lymphoma Research Foundation and Lymphoma Canada. She is currently an Associate Editor at Haematologica. Dr. Savage's research interest areas include, peripheral T-cell lymphomas, Hodgkin lymphoma and primary mediastinal large B-cell lymphoma including research in the AYA age group, as well as investigating predictors of central nervous system relapse in diffuse large B-cell lymphoma.

Select publications in PTCL

Savage KJ, Chhanabhai M, Gascoyne RG, Connors JC. Characterization of peripheral T-cell Lymphomas in single North American institution by the WHO classification. Annals of Oncology. 2004; 15:1467-1475. (PMID: 15367405)

Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO and Weisenburger DD for the International Peripheral T-cell lymphoma Project. ALK-negative Anaplastic Large-cell Lymphoma (ALCL) is Clinically and Immunophenotypically Different from both ALK-positive ALCL and Peripheral T-cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-504. (PMID: 18385450

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, **Savage KJ**. Survival of Patients with Peripheral T-cell Lymphomas (PTCL) following First Relapse or Progression: Spectrum of disease and rare long-term survivors. Journal of Clinical Oncology. 2013;31(16):1970-6. (PMID: 23610113)

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, **Savage KJ**. Identification of high-risk DUSP22 rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. PMID: 30873584. SA

Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen SLS, Zinzani PL, Truemper LH, Illidge TM, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer SP. Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2. Blood Adv. 2022 Apr 25:bloodadvances.2020003971. doi: 10.1182/bloodadvances.2020003971. Epub ahead of print. PMID: 35470385

Domingo-Domenech E, Pro B., Illidge T, Horwitz S, Trumper L, Iyer S, Advani R, Barlett NL, Christensen JH, Kim WW, Feldman T, Choi I, Gritti G, Belada D, Shustov A, Illes A, Zinzani PL, Huttmann A, Trneny M, Le Gouill S, Jagadeesh D, Friedberg JW, Little M, Don C, Fanale M, Fenton K, **Savage KJ** Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: a subgroup analysis of the ECHELON-2 study at 5 years' follow-up. Blood Cancer J. 2025 Aug 1; 15(1):129. PMID: 40750774

Professor SINGH Gill Harinder Harry

Clinical Associate Professor

MBBS (HK), PDipID (HKU), MD (HK), MRCP (UK), FRCP (Edin, Glasg, Lond), FRCPath, FHKCP, FHKAM (Medicine)

Biography

Gill Harinder Singh Harry, MD, PhD, is currently Clinical Associate Professor at the Department of Medicine, School of Clinical Medicine, the University of Hong Kong. He graduated in 2006 and joined Queen Mary Hospital in 2007. Dr. Gill completed his Haematology and Haematological Oncology training in 2014, followed by Haematopathology training from 2017 to 2019. He earned his PhD in 2019, focusing on the genomics of myeloproliferative neoplasms and became the First Fellow in Genetics and Genomics (Medicine) in 2023.

He has published extensively in esteemed peer-reviewed journals, including Blood, Blood Advances, Haematologica, British Journal of Haematology, Bone Marrow Transplantation, Annals of Oncology, Journal of Clinical Oncology, Cancer and Science Translational Medicine. He is one of the founding members and directors of the Asian Myeloid Working Group leading key regional studies on myeloid malignancies in Asia including the Asian MDS Genomics Registry, the APL Asian Consortium Study, and the Asian MPN Registry.

Curriculum Vitae

Name: Hung (Harry) Chang

Education: Taipei medical college, Taipei, Taiwan.

Current Position: Attending Physician, Hematology Division, Internal Medicine Department, Chang Gung Memorial Hospital (CGMH), Taoyuan, Taiwan
Associate Professor, Chang Gung University, Taoyuan, Taiwan.
Associate Professor, Ching Hwa University, Hsin Chu City, Taiwan.
Supervisor, Center for Quality Management, Chang Gung Memorial Hospital, Taiwan
Deputy Editor-in-chief, Chang Gung Academic Report

Bibliography:

1. **Chang H**, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. European journal of haematology 2012;88:321-8.
2. **Chang H**, Yanachkov IB, Dix EJ, et al. Modified diadenosine tetraphosphates with dual specificity for $P2Y_1$ and $P2Y_{12}$ are potent antagonists of ADP-induced platelet activation. Journal of thrombosis and haemostasis : Journal of Thrombosis and Haemostasis 2012;10:2573-80.
3. **Chang H**, Tang TC. Surgical site spread of skeletal diffuse large B-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:e141-3.
4. **Chang H**, Yanachkov I, Dix EJ et al. Antiplatelet Activity, $P2Y_1$ and $P2Y_{12}$ Inhibition, and Metabolism in Plasma of Stereoisomers of Diadenosine 5',5'''-P^1,P^4-dithio-P^2,P^3-chloromethylenetetraphosphate. PLoS One 2014 Apr 10;9(4):e94780.
5. Ou C, **Chang H (corresponding author)**, Hung YS, Kuo MC, Li PL, Lin TL. Changing profile of platelet activity and turnover indices during treatment response of immune thrombocytopenia. Clin Exp Med. 2022.
6. Chen NC, **Chang H (corresponding author)**, Kao HW, Ou CW, Kuo MC, Wang PN, Lin TL, Wu JH, Hung YS, Su YJ, Ong YC, Shih HJ. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma. *Clinical and experimental medicine*. 2023. 10.1007/s10238-023-01061-w.
7. Shih HJ, Kuo MC, Lin TL, Kao HW, Wu JH, Hung YS, Ou CW, Su YJ, **Chang H (corresponding author)** (2023) Major impact of prognosis by age and sex in patients with primary mediastinal large B-cell lymphoma. Oncol Lett (Published online on: December 13, 2023 https://doi.org/10.3892/ol.2023.14190)
8. Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, **Chang H**, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024 Nov 16;404(10466):1940-54.
9. A Cuker, T Stauch, N Coope, H Al-Samkari, M Michel, W Ghanima, P Urban, J Fronczek, M Foster, M Weill, L Zhang, M Hou, M.D, T Zander, A Sharif, J Sun, U Kumar, R Schutgens, E Rossi, L Deleu, L Červinek, JH Yoon, **H Chang** et al. Ianalumab Plus Eltrombopag for Second-Line Treatment of ITP. New Engll J Med 2025 (Accepted).

CURRICULUM VITAE

1. Name: Jae-Ho Yoon, M.D., Ph.D.

2. Hospital: Seoul St. Mary's Hospital, Catholic University of Korea, Hematology Department

3. Fields of interest: Acute leukemia, Haemophagocytic lymphohistiocytosis, Lymphocytic disorder,

4. Education

2014~2016 Graduation from College of Medicine, The Catholic University of Koreaq

2010~2014 (M.D., Ph.D.) The Catholic University of Korea

1997~2003 (M.S) The Catholic University of Korea

5. Professional activities

(2020–Present) Associate Professor, Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea

(2022) Research Fellow, Prof. Lee's CAR-NK Laboratory, University of Ottawa, Canada

(2021) Research Fellow, Prof. Brentjens' CAR-T Laboratory, Memorial Sloan Kettering Cancer Center, US

(2014–2019) Assistant Professor / Clinical Assistant Professor, Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea

[Awards & Honors]

2012 Best Presentation Award, The Korean Society of Hematology

2013 Best Presentation Award, The Korean Society of Blood and Marrow Transplantation

2015 Outstanding Paper Award, The Korean Association of Internal Medicine

2017 Outstanding Researcher Award, The Korean Society of Hematology

2018 Outstanding Researcher Award, The Korean Society of Blood and Marrow Transplantation

2020 Outstanding Paper Award, The Korean Society of Hematology

2022 Best Oral Presentation Award, The Korean Society of Blood and Marrow Transplantation

6. Membership in professional societies

Member of the Korean Society of Hematology

Member of the Korean Association of Internal Medicine

Member of the Korean Society of Blood and Marrow Transplantation

Scientific Committee Member, Acute Lymphblastic leukemia Research Group, The Korean Society of Hematology

Member of the American Society of Hematology (ASH)

7. Publication

<Textbook>

December 2017, Hematology Textbook, The Korean Society of Hematology, Panmun Education (Co-author)

December 2012, Myelodysplastic Syndromes: Insights from Hematology Specialists, Elsevier Korea L.L.C. (Co-author)

July 2019, (Current Principles and Clinical Practice of) Internal Medicine: Clinical Practice Guidelines, Gunja Publishing (Co-author)

<Journal articles>

- Lee H, Han JH, Kim JK, Yoo J, Cho HS, Yoon JH, Cho BS, Kim HJ, Lim J, Jekarl DW, Kim Y. Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study. J Clin Apher. 2023 Dec;38(6):727-737. doi: 10.1002/jca.22090. Epub 2023 Oct 3. PMID: 37786990.
- Jeon Y, Kim TY, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Cho SG. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients. Cytotherapy. 2023 Dec;25(12):1307-1316. doi: 10.1016/j.jcyt.2023.07.005. Epub 2023 Aug 4. PMID: 37542512.

William G. Wierda

Dr. Wierda is uniquely qualified to be the Principal Investigator (PI) for this grant owing clinical and translational research and expertise in CLL. In 2001, Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC. He was promoted to Associate Professor of Medicine in 2007. In 2012, he was promoted to Professor of Medicine and continue clinical and translational research in CLL. Dr. Wierda's outpatient clinical activities are more than 90% dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been PI, Co-PI, or collaborator on numerous clinical trials and conduct translational research in CLL. He has published many peer-reviewed articles on various clinical and translational aspects of CLL and drug development and have given numerous lectures on treatments for patients with CLL. Dr. Wierda's particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.

Philip A. Thompson, MD

Associate Professor of Leukemia

Dr. Philip A. Thompson is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, USA, and a board-certified hematologist–oncologist.

He received his medical degree from The University of Texas Southwestern Medical School and completed his internal medicine residency at Brigham and Women's Hospital, Harvard Medical School, followed by a hematology and medical oncology fellowship at MD Anderson Cancer Center.

Dr. Thompson is an internationally recognized expert in chronic lymphocytic leukemia (CLL) and other lymphoid malignancies, with a strong focus on novel targeted therapies, BTK inhibitors, BCL-2 inhibitors, and mechanisms of treatment resistance. He has been a principal investigator and co-investigator in numerous landmark clinical trials that have helped shape modern CLL treatment paradigms.

He has authored and co-authored many influential publications in high-impact journals, and is an active contributor to international guidelines and educational programs. Dr. Thompson is widely regarded for his clinical expertise, translational research, and commitment to advancing precision medicine in hematologic malignancies.

Dr. Danny Hsu

consultant clinical and laboratory haematologist whom completed his medical degree at Monash University in Australia. After his basic physician training in Melbourne, he permanently relocated to Sydney and became a Fellow of the Royal Australasian College of Physicians and The Royal College of Pathologist Australasia after completing training in clinical and laboratory haematology at St. George Hospital and Royal Prince Alfred Hospital.

Since 2011, Hsu has been a staff specialist at Liverpool Hospital where he is the current Director of Therapeutic Apheresis and Clinical Lead of Immune Haematology. He has extensive experience in the management of malignant and general hematological conditions, with a particular interest in rare diseases. Due to his clinical and research expertise, Hsu has been a member of various international and national pharmaceutical industry advisory boards for rare hematological diseases (i.e. paroxysmal nocturnal hemoglobinuria, atypical hemolytic uraemic syndrome, immune thrombocytopenic purpura and thrombotic microangiopathies). He is also a current sitting council member of the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ).

Hsu remains active in clinical research and is also passionate about education. He is a Conjoint Lecturer at the University of NSW and actively participates in mentoring, as well as lecturing for the School of Medicine. He is also the co-founder of “Young Blood, a volunteer organization which assists in clinical teaching for hematology trainees, as well as to facilitate networking amongst the next generation of hematologists.

Bing Han, MD, PhD

Professor and Chief Physician, Department of Hematology
Peking Union Medical College Hospital (PUMCH)

Dr. Bing Han is a Professor and Chief Physician in the Department of Hematology at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, and is a highly influential clinician and academic leader in the field of hematology in China.

He has long been dedicated to the clinical care and research of hematologic malignancies as well as complex and rare hematologic disorders. His areas of expertise include lymphoma, leukemia, multiple myeloma, and hematopoietic stem cell transplantation, and he has played key roles in numerous national and international multicenter clinical studies.

Dr. Han has published extensively in high-impact international peer-reviewed journals and is actively involved in the development of national and international hematology treatment guidelines. He serves as an important member of multiple national academic societies and professional committees, and is deeply committed to physician training and medical education, playing a pivotal teaching and leadership role within the Peking Union Medical College system.

Dr. Naval G. Daver

Dr. Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr. Daver has published more than 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.

Ayalew Tefferi, M.D.,

The research of Ayalew Tefferi, M.D., focuses on the pathophysiology, natural history and treatment of chronic myeloproliferative neoplasms (MPNs). Examples of MPNs include polycythemia vera, essential thrombocythemia and primary myelofibrosis. Dr. Tefferi's research efforts involve database and laboratory-based studies, as well as the development of new drugs for therapy.

Focus areas

Study of MPN natural history and patient outcomes. Dr. Tefferi analyzes and identifies clinical and laboratory risk factors for MPN, especially those that are predictive of patient outcomes of interest. These include fibrotic transformation, leukemic transformation and overall survival. Dr. Tefferi uses disease-specific clinical databases with long patient follow-up. He has maintained data over several decades for this purpose.

Molecular pathophysiology. Dr. Tefferi has directed research efforts for comprehensive genetic and mutational profiling of MPNs. This work has led to the development of genetic and clinical-molecular prognostic models that are in contemporary clinical use for patient care.

Novel therapeutics. Dr. Tefferi has conducted numerous clinical trials that have led to licensing of several drugs in the U.S. for MPN indications. These therapeutic agents include ruxolitinib and momelotinib for the treatment of myelofibrosis.

Study of rare diseases. Dr. Tefferi has led many studies of rare MPNs. These included systemic mastocytosis, eosinophilic conditions, histiocytic disorders and hemophagocytic lymphohistiocytosis.

Significance to patient care

Chronic myeloproliferative neoplasms (MPNs) make up a group of relatively uncommon diseases with overlapping clinical and biological features that are poorly understood. The only curative treatment is stem cell transplantation.

Dr. Tefferi's work in this area has provided a better understanding of the mechanisms of these diseases. This research has helped identify patient characteristics that predict disease-related complications. His studies have played a part in the development of new treatments for these diseases.

Dr. Tefferi's contributions have had a major impact on patient care. His research has been widely adopted by MPN experts and used to develop international guidelines. In addition, Dr. Tefferi's work on rare MPNs, such as systemic mastocytosis and eosinophilic disorders, has advanced the understanding of disease biology and assisted in the development of rational treatment strategies for these diseases.

Dr. Tefferi also promotes patient care by helping other healthcare professionals hone their expertise. He has served as a key faculty member of many national board review courses, including those sponsored by Harvard Medical School, The University of Texas MD Anderson Cancer Center and George Washington University.

Professional highlights

Physician author, MPN content, UpToDate, 2022.

Barbara Woodward Lips Professor II, Mayo Clinic, 2020.

Henry M. Stratton Medal for Clinical/Translational Science, American Society of Hematology, 2016.

Dr. Garcia-Manero

For the last 25 years, Dr. Garcia-Manero's effort has focused on improving the outcomes and quality of life of patients with leukemia and in particular myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in an attempt to develop new therapeutic interventions. He currently leads the largest MDS program in the world and directs the MDS/AML Moon Shot® program at MD Anderson. This work has resulted in over 1,000 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.

Professor TSE Wai Choi, Eric

Professor Tse is Clinical Professor and Specialist in Haematology and Haematological Oncology. He graduated MBBS with John Anderson Gold Medal from the University of Hong Kong. He also received his doctorate training from the University of Cambridge, and was awarded Max Perutz Research Prize by the MRC Laboratory of Molecular Biology, Cambridge. Upon completion of clinical training, Professor Tse has been appointed honorary consultant physician in the Department of Medicine, Queen Mary Hospital.

His basic and translational research focus on the development of novel therapeutic approach in cancer treatment through identifying potential targets and understanding the fundamental biology of cancer cell. Professor Tse has pioneered the development of intracellular antibodies in the therapy of cancer during his early stage of career. He is currently examining the role of peptidyl-prolyl-isomerase PIN1 and investigating the therapeutic potential of arsenic trioxide in cancers. In addition to his laboratory work, Professor Tse is also active in clinical research on lymphoid neoplasms and cancer-associated thrombosis.

John P. Leonard, MD

As a hematologist and medical oncologist at NYU Langone, I am dedicated to providing personalized and compassionate care to my patients. I specialize in treating patients with various forms of lymphoma, including non-Hodgkin's lymphoma and Hodgkin lymphoma. My expertise extends to managing complex cases in which patients may have concurrent medical conditions that can complicate cancer treatment. My approach centers on understanding patients' unique needs and collaborating with them to devise the most effective treatment plans.

Patients often seek treatment at the Perlmutter Cancer Center and NYU Langone, whether they're from the New York area, the surrounding region, or traveling from other parts of the country and the world, to be evaluated and treated for lymphoma by our team. We are not a "factory," moving patients through as if they are boxes in a warehouse. Instead, we take the time to get to know our patients, and partner with them to devise the best available evaluation and treatment program. While we are aware of guidelines, treatment algorithms, and institutional programs and regimens, we focus on what is best for each individual patient.

Our hematopathology group, which is responsible for diagnosing and evaluating biopsies of lymphomas and other blood cancers, is recognized for their diagnostic and research expertise. They are part of a pathology team that provides state of the art diagnostic capabilities. Similarly, our lymphoma program is internationally recognized for our efforts to enable patients with non-Hodgkin's lymphoma, Hodgkin lymphoma, and related disorders to have the best possible clinical outcome. We have helped to establish standards of care practiced across the US. Our group has also played a role in developing nearly every drug that has been FDA approved for lymphoma therapy in the last decade. Through clinical trials, many of our patients were among the first in the world to receive these cutting-edge therapies.

Moreover, we are leaders of the Lymphoma Committee of National Cancer Institute (NCI)-supported Alliance for Clinical Trials in Oncology within the NCI's National Clinical Trials Network. In this capacity, and through the NCI Lymphoma Steering Committee, we lead NCI-sponsored trials being conducted at major medical centers across the US that will establish the next generation of therapies.

My journey into medicine was driven by a passion for science and a desire to ease suffering. I chose hematology and medical oncology because of the opportunity to address system

Luhua (Michael) Wang, M.D.

I am a Professor in the department of Lymphoma & Myeloma at MD Anderson. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I completed my clinical training as a resident at Norwalk Hospital, Norwalk, Conn., and as a Fellow in Oncology and in Hematology at MD Anderson.

I have published more than 150 peer-reviewed papers and have presented my work at meetings nationally and internationally. I am the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.

During the past 15 years, I have focused on preclinical and clinical research and established a MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. My clinical research of the Bruton's tyrosine kinase inhibitor ibrutinib was published in the New Eng. J. Med. in 2013. I am currently acting as National PI of the multisite international phase 5 registration trial for ibrutinib in MCL. I am also the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.

Kohei Hosokawa M.D.

Associate professor

Institution:

Kanazawa University Hospital

Online Profile:

https://ridb.kanazawa-u.ac.jp/public/detail_en.php?id=4614

Primary Disease Area of Focus:

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Practice Location:

Kanazawa University Hospital

Kanazawa , 17 920-8641 ,

JP

Physician Status:

accepting new patients

Other pages on our site that mention Kohei Hosokawa:

1. Grant Recipient - Kohei Hosokawa, MD, PhD
2. Research Article - High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag
3. Webinar - Ninth International Bone Marrow Failure Disease Scientific Symposium

Personalized Search

John F. DiPersio, MD, PhD

Virginia E and Sam J Golman Professor; Section Director – Cellular Therapy

Education

- ☐ 1980: MD/PhD in Microbiology, University of Rochester, Rochester, NY
- ☐ 1973: BA in Biology (Magna Cum Laude), Williams College, Williamstown, MA

Post-Graduate Training

- ☐ 1987-1984: Fellow, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA
- ☐ 1984-1983: Chief Resident, Parkland Memorial Hospital, UT Southwestern, Dallas, TX
- ☐ 1983-1981: Resident, Parkland Memorial Hospital, UT Southwestern, Dallas, TX
- ☐ 1981-1980: Intern (Straight Medicine), Parkland Memorial Hospital, UT Southwestern, Dallas, TX

Academic Positions

- ☐ present-2017: Director, Center for Gene and Cellular Immunotherapy (CGCI), Washington University School of Medicine, St. Louis, MO
- ☐ present-1997: Professor of Medicine, Pediatrics and Pathology/Immunology, Washington University School of Medicine, St. Louis, MO
- ☐ 2022-2000: Chief, Division of Oncology, Washington University School of Medicine, St. Louis, MO
- ☐ 2022-2000: Deputy Director, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
- ☐ 2000-1997: Acting Director, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
- ☐ 2000-1994: Chief, Division of Bone Marrow Transplantation & Stem Cell Biology, Washington University School of Medicine, St. Louis, MO
- ☐ 1994-1990: Director, Bone Marrow Transplant Program, Strong Memorial Hospital, Rochester, NY
- ☐ 1994-1990: Assistant Professor of Medicine, Hematology Unit, University of Rochester School of Medicine, Rochester, NY

Prof. Allen Yeoh

Designations:

- ☐ Head of Division & Senior Consultant, Division of Paediatric Haematology and Oncology, Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Hospital
- ☐ Head & Senior Consultant, Division of Paediatric Haematology and Oncology, National University Cancer Institute, Singapore
- ☐ Professor, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore
- ☐ Viva-Goh Foundation Professor in Paediatric Oncology, Yong Loo Lin School of Medicine, National University of Singapore

Qualifications:

MBBS (S'pore), MMed (Paeds) (S'pore)

Specialties/Sub-specialties:

Paediatric Haematology & Oncology, Paediatric Medicine

Clinical Disciplines/Programmes:

Paediatric Blood & Marrow Transplantation (BMT) Programme, Paediatrics, Paediatrics – Children's Emergency

Special Interests:

Pharmacogenomics in childhood leukemias, treatment-related toxicities in childhood leukemias

Journals & Publications

1. Lazaro AM, Xiao Y, Masaberg C, Hwang WY, Yeoh AE, Weiyan Y, Ng J, Hurley CK, Posch PE. Novel HLA class I and II alleles identified during routine registry typing. Tissue Antigens,2011 Jul 5
2. Jiang N, Kham SK, Koh GS, Suang Lim JY, Ariffin H, Chew FT, Yeoh AE. Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL). J Proteomics. 2011 May 16;74(6):843-57. Epub 2011 Mar 21.
3. Chan, J.Y-S., Ugrasena, D.G., Lum, D.W-K., Lu, Y. and Yeoh, A.E-J. Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children. Hematological Oncology, 2010 Sep 7

Prithviraj Bose, M.D.

Department of Leukemia, Division of Cancer Medicine

After obtaining his medical degree in 2001 from the University of Calcutta in his hometown of Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose began a residency in general medicine at the Institute of Post-Graduate Medical Education and Research in Kolkata, which he left in early 2004 to move to the United States. He then completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington in 2005, and residency at the Henry Ford Hospital in Detroit, Michigan in 2007, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma from 2017 through 2010. Dr. Bose became American Board of Internal Medicine-certified in hematology and medical oncology in 2010.

He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center between July 2010 and January 2015. At VCU, Dr. Bose took care of patients with diverse hematologic malignancies and teamed up with noted translational scientist, Steven Grant, to design early phase clinical trials of novel, targeted drug combinations in AML.

In the Department of Leukemia at The University of Texas MD Anderson Cancer Center, which he joined in early 2015, Dr. Bose's major clinical and research focus is on myeloproliferative neoplasms (MPNs). He works closely with Dr. Srdan Verstovsek, chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis. He has presented his research at international conferences and regularly speaks on MPN topics. Dr. Bose's other area of interest is chronic lymphocytic leukemia (CLL). His clinical practice consists largely of patients with MPNs or CLL, although he also treats many patients with MDS, CML and acute leukemias.

Hagop M. Kantarjian, M.D.

Department of Leukemia, Division of Cancer Medicine

Dr. Kantarjian is a professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute.

Dr. Kantarjian has received several prestigious honors and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the AACR Joseph H. Burchenal Memorial Award (2013),the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). He received the ASCO David A. Karnofsky Memorial Award for lifelong contributions to leukemia research and patient care (2023).

Dr. Kantarjian's research focuses on translational-clinical developmental therapeutics in leukemia. In the past four decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 2,400 peer-reviewed publications.

Caron Jacobson MD

Dana-Farber Cancer Institute

Boston, Massachusetts
United States

I graduated from Columbia College of Physicians & Surgeons, where I stayed for Internal Medicine residency training/chief residency before moving to Boston for fellowship training in hematology/oncology at Dana-Farber/Mass General Cancer Center. I stayed on as faculty in the lymphoma program at Dana-Farber and am now an Assistant Professor of Medicine at Harvard Medical School. My research interests are in the clinical and translational study of immunotherapies for lymphoma, with a particular interest in cellular immunotherapies. I also serve as the Medical Director of the Immune Effector Cell Therapy program at Dana-Farber, which houses our commercial and research cell therapy programs across the Institute. I am the principal investigator of industry-sponsored and investigator-initiated clinical trials involving cellular therapies for lymphoma, and lead retrospective and translational studies to identify mechanisms of response and resistance to these therapies.

Dr. Kate Cwynarski

Location: University College Hospital

Professional background

- ☐ Trained at King's College, Hammersmith Hospital and Royal Free Hospitals.
- ☐ MRC Clinical Research fellowship PhD at Imperial College, London.
- ☐ Lead of the UK CNSL group and a member of the NCRI Lymphoma CSG.
- ☐ Chair of the BSH Lymphoma Specialist Interest Group.
- ☐ Highly involved in clinical trials in lymphomas.

Specialties

- ☐ Blood cancers and conditions (clinical haematology)
- ☐ Chronic lymphocytic leukaemia (CLL)
- ☐ Lymphoma

Research interests

- ☐ CNS lymphoma
- ☐ HIV-related lymphoma
- ☐ High-grade B-cell lymphomas
- ☐ T-cell lymphomas

Selected Publications

- ☐ Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, **Cwynarski K**, McKay P.Wilson MR, et al. Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.2020002421.Blood Adv. 2020. PMID: 32761231.
- ☐ The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. McKay P, Wilson MR, Chaganti S, Smith J, Fox CP, **Cwynarski K;** British Society of Haematology.McKay P, et al. Br J Haematol. 2020 Sep;190(5):708-714. doi: 10.1111/bjh.16866. Epub 2020 Jul 15.Br J Haematol. 2020. PMID: 32433789 No abstract available.